RecruitingVenous StenosisVenous Occlusion
WRAP North America
Eligible age
18+ yrs
Accepts
All genders
Locations
10 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this observational study is to investigate the safety and efficacy of the WRAPSODY CIE in a real-world North American population. Participants treated with the WRAPSODY CIE device in accordance with the device instructions for use will be followed in accordance with standard of care up to 3-years post-procedure.
Sponsor: Merit Medical Systems, Inc.
You may qualify if…
- ✓ 1. Subject provides written informed consent for study participation.
- ✓ 2. Subject is male or female, with an age ≥ 18 years at date of enrollment.
- ✓ 3. Subject is willing to comply with site standard of care procedures and follow-up visit schedules over 36 months.
- ✓ 4. Subject is undergoing chronic hemodialysis with the hemodialysis access the intervention will be performed upon.
- ✓ 5. The dialysis access is considered mature and has been used to deliver hemodialysis treatments for at least one session.
- ✓ 6. Subject has stenosis or occlusion within the dialysis outflow circuit and is treated with WRAPSODY CIE in accordance with device instructions for use.
You may not qualify if…
- ✕ 1. Subject has a planned surgical revision of access site.
- ✕ 2. Subject has a known or suspected infection of the hemodialysis access site, systemic infection and/or septicemia.
- ✕ 3. Subject has an uncorrectable coagulation disorder.
- ✕ 4. Known hypersensitivity to nickel or titanium.
- ✕ 5. Subject's hemodialysis access is anticipated to be abandoned within 6 months.
- ✕ 6. Subject is scheduled for kidney transplant or peritoneal dialysis within the next 6 months post-procedure.
- ✕ 7. Full expansion of a PTA balloon cannot be achieved during predilatation.
- ✕ 8. Device would be placed in the Superior Vena Cava
Where it's recruiting
Alabama
Dothan
Arizona
Phoenix
California
Riverside
Florida
Jacksonville · Sarasota
Kentucky
Lexington
Rhode Island
Providence
South Carolina
Charleston · Orangeburg · Spartanburg
Tennessee
Memphis
Texas
Fort Worth · Humble · San Antonio
Virginia
Virginia Beach
Source: ClinicalTrials.gov · NCT06807099 · last updated 2026-06-17